When i was looking through this list i saw an interesting trend:
https://www.barrons.com/articles/sbv-silicon-valley-bank-biotech-a94695dd
A lot of biopharma startups are listed here, and while the ones noted here say that their holding with SVB are in really small portions i'm wondering if some of the other bioparma startups (that aren't saying anything public yet) with high valuations have higher levels of exposure and are running a risk of continuing to be a going concern or SIVB might be holding their stock that may get dumped.
250K is not enough to make payroll for a few weeks… let alone continue drug studies that are the sole reason for a Bio-pharma companies valuation.
It looks like a lot of the bio-pharma was done through their subsidiarity SVB securities:
https://en.wikipedia.org/wiki/SVB_Securities
Heres a list of companies that SVB was serving as the bookrunner for in the last few months:
https://www.svbsecurities.com/category/deal-announcement/
CWAN, RVMD, TVTX, TSVT, ABVX, CVAC, ROIV, AVTX, OLK, REPL, RXDX, LNTH, AURA,SGRY, NTRA
Does anyone know if SVB being the bookrunner means that these stock offering funds may be locked in an SVB account?
There is also other bio-pharama companies that got lines of credit through SVB like this one:
What do you guys think? am i barking up the wrong tree on this one, or is this an area worth further inspection?
(Also as an aside… apparently SVB was involved with the premium wine businesses as well, might be a area worth further exploration, but not sure how to make money off that information)
Leave a Reply